Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2015

View Archived Issues

Phase Ib trial set to evaluate tolerogenic dendritic cells for MS and neuromyelitis optica

Encouraging results on S-44858 for the treatment of CNS diseases

Inotek Pharmaceuticals provides update on development strategy for trabodenoson

Chugai updates pipeline progress of second quarter 2015

DiffronC Technology targeting NR2F6 shows potential for the treatment of leukemia

PharmaMar forms license agreement with TTY Biopharm for Aplidin

CEA-Leti and Diabeloop to develop artificial pancreas to improve diabetes treatment

Novel GSM shows promise for the treatment of AD

Brincidofovir reduces mortality in animal model of smallpox

Cara Therapeutics reports data from phase II trial in uremic pruritus

Norgine patents CCR9 antagonists

Purdue Pharma discloses opioid receptor agonists

Merck & Co. develops ROMK channel blockers

Polyphor divulges selective elastase inhibitors

Lifesci Pharmaceuticals reports KLKB1 inhibitors

Model created to investigate the role of butyrylcholinesterase in Alzheimer's disease

Bristol-Myers Squibb describes IRAK-4 inhibitors

EMA accepts for review MAA for grazoprevir/elbasvir in HCV

Sunesis updates regulatory progress for vosaroxin in AML

EMA committee adopts positive scientific opinion for Mosquirix

Inovio and EORTC to conduct phase II trial of INO-3112 in cervical cancer

Janssen files sNDA for reduced-duration treatment with simeprevir in HCV infection

New preclinical study investigates PharmaCyte's treatment in ascites

Baxalta acquires asparaginase portfolio from Sigma-Tau

Amgen submits sNDA for Kyprolis in relapsed multiple myeloma

AstraZeneca forms partnership with inhaler monitoring company Adherium

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.